ATXN3 and Machado-Joseph disease: The authors demonstrated that LTG decreased mutant ataxin-3 levels in vitro, concluding that LTG elicits a positive response in MJD patients with mild truncal ataxia through its pharmacological action involving the downregulation of mutant ataxin-3 [5].